The global biosimilar market is undergoing a meaningful shift toward an “analytical-first” approach, making rigorous biosimilar planning more critical than ever. Regulatory agencies increasingly accept that comprehensive analytical characterization can establish biosimilarity without requiring large Phase III trials, though this is not yet universally applied across all molecule types. This evolution comes as more than $80 billion in biologic revenues face biosimilar competition through 2030.

Biosimilar developers and manufacturers must recognize that development models used a decade ago may no longer align with current regulatory expectations. Therefore, given this evolving landscape, teams that fail to adapt risk unnecessary consequences. As a result, continuing with older approaches can lead to unnecessary spending on studies that regulators may not require, depending on the product and available evidence.

This article covers three areas essential to modern biosimilar planning:

Strategies: How to select targets, handle patents, and structure analytical work;
Trial design: What clinical evidence regulators actually require now, and under what conditions requirements can be reduced.
Regulatory convergence: How FDA, EMA, and WHO frameworks align, and where meaningful differences remain.

But before we look at these topics in depth, let us first understand how the regulatory environment for biosimilars has evolved through a series of guidance documents, reflection papers, and accumulated precedents published primarily between 2022 and 2025.

How will the 2025 regulatory shifts redefine biosimilar development?

The 2025 regulatory shifts represent a fundamental transformation in biosimilar development. The key changes include:

Inversion of the evidence hierarchy: Analytical characterization is now the most important evidence for proving biosimilarity. Researchers mainly use clinical studies, such as pharmacokinetic (PK) and immunogenicity trials, to confirm findings and address any remaining uncertainties.
Waiver of phase III confirmatory trials: Large Phase III efficacy trials are no longer an automatic requirement. Where developers demonstrate strong analytical similarity and PK equivalence, and the mechanism of action is well understood, regulators, including the FDA and EMA, may grant waivers. This is a product-specific determination, not a universal policy change. Therefore, molecules with complex mechanisms, narrow therapeutic indices, or limited analytical characterization will still require clinical confirmatory evidence.
Reduced reliance on mandatory switching studies: Dedicated switching studies are no longer mandatory for most biosimilars seeking interchangeability status in the United States. Analytical data and PK bridging studies can often support interchangeability, making the process faster and more cost-effective for eligible products.
Global regulatory convergence: The FDA, EMA, and WHO have increasingly aligned their scientific standards. And so, this allows companies to design one core development program that can support approvals in multiple regions, reducing duplication and cost.
The Inflation Reduction Act (IRA) “Statutory Cliff”: Under the Inflation Reduction Act, Medicare can negotiate drug prices after a defined period post-approval: 9 years for small-molecule drugs and 13 years for biologics. This pricing pressure operates independently of patent protection and reshapes commercial timing and revenue expectations for both originators and biosimilar developers. As a result, this creates additional urgency around biosimilar market entry timing for products approaching those thresholds.
Enhanced data integrity requirements: Regulators now require a full “data lifecycle” approach. And so developers must maintain complete metadata and audit trails showing how data was generated, processed, and managed from start to submission.
Expansion of regulatory transparency: The FDA has expanded its Product-Specific Guidance (PSG) database, giving developers clearer expectations and reducing uncertainty for both standard and complex biologics.
Standardization of indication extrapolation: Regulators have strengthened the framework for extrapolation. Hence, a biosimilar can now be approved for all indications of the reference product based on strong analytical and pharmacological justification, without requiring separate trials for each indication.

Now that the regulatory landscape is clear, the next section explores the strategic approach to modern biosimilar development.

Strategic framework for biosimilar development

Since the 2025 regulatory updates, high-resolution molecular characterization has become the primary basis for demonstrating biosimilarity. While clinical studies now play a targeted and confirmatory role.

A modern strategic framework follows five structured steps as follows:

Step 1: Target selection and commercial viability

Development begins with selecting the right molecule. This decision determines cost, risk, and long-term success.

A strong biosimilar target should meet four criteria:

Patent clarity
Developers must assess “patent thickets” covering the molecule, formulations, manufacturing processes, and devices. Hence, a Freedom-to-Operate (FTO) analysis should be conducted early to avoid unexpected litigation delays.
Scientific maturity
The reference product should be well-characterized in published literature. Because molecules with unclear structure–function relationships carry higher regulatory uncertainty.
Commercial potential
With development costs of approximately $80–150 million (for monoclonal antibodies), the market must justify investment. This requires evaluating:
- Current sales volume
- Number of competing biosimilars
- Expected launch timelines
Regulatory precedent
Products with previously approved biosimilars have clearer pathways. This is because, first-in-class biosimilars require more regulatory engagement and carry greater uncertainty.

Step 2: Intellectual property strategy

Intellectual property is a strategic design constraint. It does not operate in isolation but directly shapes regulatory strategy, development timelines, and commercialization risk.

In the United States, this interaction is particularly evident in the decision of whether to participate in the Biologics Price Competition and Innovation Act (BPCIA) framework. Enacted in 2010, the Biologics Price Competition and Innovation Act created an abbreviated FDA approval pathway for biological products that are “biosimilar” to or “interchangeable” with an FDA-licensed reference product. The statute was designed to increase patient access to lower-cost, high-quality alternatives to complex and often expensive biologics, while balancing innovation incentives.

Participation in the BPCIA triggers a structured exchange of patent information between the biosimilar applicant and the reference product sponsor, commonly referred to as the “patent dance.” And therefore, this exchange significantly influences the timing of litigation, potential launch strategies, and overall market entry risk.

The strategic trade-off is:

Participate early → Greater predictability; litigation may conclude before approval
Decline participation → More flexibility, but risk of late-stage injunctions

The IP strategy should align with launch timing and commercial priorities.

Step 3: Analytical strategy and the “totality of evidence”

The most important strategic shift is the inversion of the evidence hierarchy.

Under the “Totality of Evidence” framework:

Analytical characterization is primary and
Clinical data is confirmatory

The goal is to systematically reduce scientific uncertainty through detailed molecular comparison.

Key elements include:

Mapping Critical Quality Attributes (CQAs)
These include
- Primary amino acid sequence
- Glycosylation patterns
- Higher-order structure
- Charge variants
- Biological activity

Using orthogonal methods
Independent analytical techniques should confirm each key attribute. When multiple methods produce consistent results, confidence increases, and the need for large trials decreases.

And as a result, this analytical rigor is what enables regulatory acceptance without routine Phase III studies.

Step 4: Targeted clinical trial design

With strong analytical evidence in place, clinical development becomes focused and proportionate.

Rather than repeating large efficacy trials, the goal is to address only residual uncertainty.

Phase III waivers: Large confirmatory trials are no longer automatic. They may be waived when:
- Analytical similarity is robust
- PK/PD equivalence is demonstrated
- Mechanism of action is well understood

Regulators increasingly recognize that additional efficacy trials may add statistical variability rather than meaningful evidence.

Comparative Pharmacokinetics (PK): The comparative PK study is now the primary clinical requirement. Strategic features include:
- Crossover designs (when feasible)
- Homogeneous populations to reduce variability
- Predefined equivalence margins (typically 80–125%)

PK data confirms that both products behave similarly in the body.

Pharmacodynamics (PD): Where measurable PD endpoints exist (such as receptor occupancy or validated biomarkers), comparative PD data provide additional evidence of functional equivalence. PD endpoints are molecule-specific and are not always obtainable in healthy volunteer populations, so their role varies by program. And so, PK and PD should not be treated as interchangeable concepts.

Indication extrapolation: Scientific justification achieves approval across all reference product indications rather than separate trials. This requires demonstrating:
- Shared mechanism of action
- Comparable CQAs across uses
- Similar PK and immunogenicity profiles

Therefore, when justified properly, one clinical program can support multiple indications.

Step 5: Regulatory convergence and market access

Global biosimilar development now relies on regulatory convergence.

Major agencies (FDA, EMA, WHO) agree that strong analytical data supported by targeted PK and immunogenicity studies are sufficient for approval. Hence, a global strategy should:

Design a core evidence package
Meet the most stringent common requirements
Add minimal regional adjustments

Interchangeability

In the United States, interchangeability remains commercially important because it allows pharmacy-level substitution.

Under the 2025 framework:

Mandatory switching studies have largely been removed
Interchangeability can be supported by analytical and PK evidence

As a result, this reduces cost and accelerates market entry.

The IRA “Statutory Cliff”

The Inflation Reduction Act (IRA) has introduced a structural commercial shift.

Medicare can negotiate biologic prices 13 years after initial approval (9 years for small molecules).
This timeline is independent of patent protection

As a result:

Revenue projections must account for earlier pricing pressure
Market entry timing becomes strategically critical

The IRA changes not only pricing, but also the competitive urgency of biosimilar entry.

The following table summarizes the entire strategic framework for biosimilar development:

Strategic Pillar	Key Components & Considerations	Developer Implications
1. Target Selection & Market Viability	Patent Clarity: Early Freedom-to-Operate (FTO) analysis to navigate “patent thickets”. Molecule Characterization: Choosing targets with well-understood structure-function relationships. Commercial Scale: Assessing the landscape to justify $80–150M in investment.	Early analysis prevents litigation delays; established regulatory precedents reduce development risk.
2. Intellectual Property (IP) Strategy	The “Patent Dance”: Strategic decision to engage in the optional BPCIA information exchange. Lifecycle Management: Navigating secondary patents on formulations and delivery devices.	Non-participation preserves optionality but risks eleventh-hour injunctions; early participation provides launch certainty.
3. Analytical Foundations (Primary Evidence)	CQA Mapping: Comprehensive assessment of Critical Quality Attributes (e.g., glycosylation, charge variants, biological activity). Technological Orthogonality: Using multiple independent methods (e.g., HDX-MS, Native MS) to close uncertainty.	High-resolution analytical data now sits at the top of the evidence hierarchy, potentially supporting a waiver for Phase III trials in cases where residual uncertainty is low. Waivers are product-specific, not universal.
4. Targeted Clinical Architecture	Phase III Waivers: Confirmatory trials are now the exception, reserved for molecules with “residual uncertainty”. Comparative PK/PD: Serving as the definitive clinical evidence using sensitive, homogeneous populations. Immunogenicity: Multi-tiered ADA screening (Screening → Confirmatory → Titration → Neutralization).	Clinical programs are designed to be proportionate to residual scientific risk, significantly compressing timelines and costs.
5. Regulatory Convergence & Access	Global Harmonization: Alignment of FDA, EMA, and WHO frameworks on an “analytical-first” approach. Indication Extrapolation: Approval across all reference indications based on a shared mechanism of action. Interchangeability: Removal of mandatory switching studies for pharmacy-level substitution status.	Developers can design a single “convergence architecture” for global filings, reducing jurisdictional duplication.
6. Economic Context	The IRA “Statutory Cliff”: Medicare pricing negotiations after 9 years (small molecules) or 13 years (biologics). Societal Value: Framing the HTA case around QoL recovery and caregiver burden reduction.	Pricing power is now severed from legal exclusivity, reordering the commercial timing logic for biosimilar entry.

Clinical trial design considerations for biosimilars:

The design of clinical trials for biosimilar development has undergone a fundamental transformation, transitioning from a model of comprehensive efficacy testing to a targeted evidence model. As a result of this shift, the role of clinical trials has been significantly redefined. High-resolution analytical characterization now determines biosimilarity, with clinical trials serving only a confirmatory role. Regulators recognize that when analytical similarity and PK bioequivalence are established, large-scale Phase III trials add statistical noise rather than meaningful scientific insight.

The following steps outline the contemporary trial design process for biosimilar development:

1. Analytical de-risking and regulatory alignment

Before initiating clinical trials, developers must build a comprehensive analytical package.

CQA identification: Identify Critical Quality Attributes (CQAs), the molecular properties that impact safety and efficacy, and characterize them using orthogonal analytical methods to eliminate uncertainty.
Early engagement: Use Pre-IND meetings (FDA) or Scientific Advice (EMA) to present analytical data and seek a formal waiver for Phase III trials. Regulators will consider and support these waivers when analytical and PK/PD equivalence are robustly demonstrated.

2. Comparative pharmacokinetic (PK) and pharmacodynamic (PD) studies

The comparative PK study is the definitive clinical deliverable for most modern biosimilar programs.

Population selection: Use homogeneous populations, such as healthy volunteers, to minimize biological variability that could mask product differences.
Study design: Researchers prefer a crossover design because it allows for a direct within-subject comparison, substantially reducing between-subject variability.
Statistical thresholds: Bioequivalence is established if the 90% confidence interval for the ratio of biosimilar to reference product for AUC and C_max falls within the 80–125% margin.

3. Tiered immunogenicity evaluation

Because structural data cannot fully predict immune responses, developers must conduct a dedicated clinical assessment.

Four-tiered testing: Evaluation follows a specific sequence:
- Screening for all potential responses,
- Confirmation to eliminate false positives,
- Titration to quantify levels, and
- Neutralizing antibody testing to assess clinical impact.
Study duration: The follow-up must be long enough to capture the full immune response trajectory, typically 6 to 12 months.

4. Strategic determination of phase III requirements

Regulators no longer require Phase III confirmatory efficacy trials as the default, thereby reserving them only for molecules with “residual uncertainty.”

Criteria for trials: A Phase III trial may be necessary if PK parameters are unreliable surrogates for clinical outcomes, if the molecule has a narrow therapeutic index, or if the mechanism of action is analytically unaddressable.
Avoiding redundancy: If the analytical and PK packages are robust, a Phase III trial is often viewed by regulators as adding “statistical noise” without adding scientific value.

5. Indication extrapolation justification

Approval for all reference product indications is sought through extrapolation, which must be explicitly justified for each use.

Scientific rationale: Developers must prove the mechanism of action is consistent across all indications and that the CQAs driving efficacy are relevant for each target pathology.

6. Post-approval infrastructure

Clinical trial design must also account for mandatory post-approval commitments.

Risk Management Plans (RMP): In regions like Europe, a formal RMP is required to monitor long-term safety and immunogenicity.
Traceability: Companies must establish systems to ensure the biosimilar is trackable by brand name and batch number to accurately attribute any post-marketing safety signals.

International regulatory harmonization in biosimilar approval

Regulatory convergence represents a fundamental shift in the global biosimilar landscape, moving away from jurisdictional isolation toward a shared scientific framework. Twenty years of accumulated regulatory experience drive this movement. Over 40 FDA approvals and more than 100 EMA approvals have consistently demonstrated that when high-resolution analytical similarity is established, clinical outcomes align.

The core principle of convergence is that analytically grounded biosimilarity, supported by targeted clinical bridging (typically PK/PD studies), is sufficient to establish clinical equivalence without requiring redundant, market-specific Phase III clinical programs. Building on this principle, major regulatory bodies worldwide are moving in the same direction. The FDA, EMA, WHO, Health Canada, and Japan’s PMDA are increasingly aligning on this “analytical-first” paradigm.

Key drivers of convergence in 2025 include:

EMA reflection papers (2024–2025): These documents formalize the position that analytical or PK/PD evidence now resolves residual uncertainty by default, reserving Phase III efficacy trials as the exception rather than the requirement.
FDA interchangeability updates: The FDA has removed the categorical requirement for dedicated switching studies for most product classes, by replacing them with a totality-of-evidence assessment focused on analytical and PK bridging data.
WHO harmonization: The WHO has updated its biosimilar guidelines to align closely with the FDA and EMA, enabling developers to design global programs with minimal jurisdictional duplication.

Strategic implementation: Regulatory convergence allows developers to use a “convergence architecture” strategy. Instead of running separate programs for each region, companies design one strong core program that meets the toughest shared scientific standards. Then, they add small, targeted data packages to address any remaining local requirements.

As a result, developers shorten timelines and reduce costs. In the past, developing a well-characterized monoclonal antibody cost about $200–300 million. However, with a streamlined, analytics-first approach and depending on molecule complexity and clinical data needs, costs can drop to roughly $80–150 million.

Comparative framework: Navigating global requirements

The table below compares FDA and EMA regulatory positions on EB therapies as of Q1 2026, highlighting areas of alignment and remaining divergence.

Requirement Area	FDA (United States)	EMA (European Union)	Strategic Convergence Approach
Analytical Package	Comprehensive CQA panel; emphasis on high-resolution orthogonal methods.	Comprehensive CQA panel; focus on equivalence-based assessment.	Design for the most stringent analytical standards to satisfy both agencies simultaneously.
Primary Clinical Evidence	Required: comparative PK/PD bioequivalence, crossover design preferred.	Required; serves as confirmatory bridging.	A single well-powered crossover PK study generally satisfies the core clinical requirement globally.
Phase III Efficacy Trials	Risk-based; increasingly waivable with robust analytical and PK data.	Formally waivable as per the 2024–2025 Reflection Papers.	Seek early scientific advice to proactively justify a waiver based on the absence of residual uncertainty.
Immunogenicity Assessment	Comparative ADA; typically requires a 12-month minimum follow-up.	Comparative ADA; 6–12 month duration is standard.	Design for a 12-month duration to ensure the data package is universally acceptable.
Interchangeability	Specific regulatory designation; switching studies are often waived in favor of bridging data.	Generally, automatic or determined at the member-state level upon approval.	Pursue the US interchangeability designation for commercial advantage in pharmacy-level substitution.
Indication Extrapolation	Accepted; requires mechanistically-linked justification for each indication.	Accepted; well-established and standardized framework.	Build a comprehensive mechanistic justification mapping CQAs to mechanisms of action across all pathologies.
Post-Approval Requirements	Risk Evaluation and Mitigation Strategies (REMS) where indicated.	Standardized Risk Management Plans (RMPs).	Implement a unified pharmacovigilance system emphasizing product-specific traceability.

Conclusion

Evolving regulatory guidance over recent years has progressively reshaped biosimilar development. Strong analytical characterization, supported by focused PK and immunogenicity studies, is now usually enough for approval. Large Phase III trials and switching studies are no longer routine requirements. Developers who invest in deep analytical work, design focused clinical programs, and plan for global approval from the beginning can reach the market faster and at lower cost. The overall goal remains the same: improving patient access to affordable biologic medicines through rigorous and efficient development.

Are you building a regulatory-aligned biosimilar development program?

Are you facing challenges in designing a PK/PD study or building a regulatory-aligned biosimilar development program? Provide your requirement details below to connect with our team to discuss your needs, and we can help you build a strategy that is scientifically rigorous and commercially efficient.